Commentary · 27 May 2026
Conference abstractPublished 12 Oct 2017
STRUCTURE-RELATED INHIBITION OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) BY FLAVONOIDS
University of Porto, Portugal
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Type 2 diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia resulting from inadequate insulin secretion and/or resistance to insulin action. Protein tyrosine phosphatase 1B (PTP1B) is considered a major negative regulator in the insulin signaling pathway, contributing to insulin resistance. Thus, the discovery and development of selective and effective PTP1B inhibitors is a potential therapeutic target for the management of type 2 DM. Some flavonoids have already been shown to inhibit this enzyme, but the literature still lacks in depth structure-activity relationship studies. The main aim of the present work was to test a diversified panel of known and new flavonoids, with different types of substituents (-OH, -OMe and/or -OBn) in different positions, against the PTP1B inhibitory activity. The evaluation of PTP1B activity was performed in vitro by monitoring PTP1B-catalyzed hydrolysis of the substrate p-nitrophenyl phosphate (pNPP) into the product p-nitrophenolate at 405 nm in a microplate reader. The study of the inhibition type of the most active flavonoid was made using the nonlinear regression Michaelis-Menten enzymatic kinetics and the corresponding Lineweaver-Burk plot. Our results suggest that that the presence of -OMe groups at positions 7 and 8 in A ring, together with the presence of -OBn groups at 3âÂ?Â? and 4âÂ?Â? positions in B ring and a OH group at 3 position in C ring, increases the flavonoidsâÂ?Â? ability to inhibit PTP1B. The most active flavonoid was 3âÂ?Â?,4âÂ?Â?-dimethoxy-7,8-dibenzoxyflavonol, presenting a mixed type inhibition. In conclusion, some of the tested flavonoids seem to be promising PTP1B inhibitors and potential effective drugs in the management of type 2 DM, increasing insulin sensitivity.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pancreatic Disorders & Therapy.
Short communication · 27 May 2026
Immunometabolic Interactions in Pancreatic Disease: Crosstalk Between Energy Dysregulation, Immune Activation, and Tissue Dysfunction
Commentary · 27 May 2026
Microvascular Dysfunction in Pancreatic Disorders: Endothelial Injury, Perfusion Failure, and Tissue Consequences
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPancreatic Disorders & Therapy
- SubjectGastroenterology & Hepatology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Carina Proença”
- BylineArticles whose byline prints “Daniela Ribeiro”
- BylineArticles whose byline prints “Marisa Freitas”
- BylineArticles whose byline prints “Joana LC Sousa”
- BylineArticles whose byline prints “Pedro A Fernandes”
- BylineArticles whose byline prints “Eduarda Fernandes”
